Comparison of Cytochrome P450 3A Enzymes in Cynomolgus Monkeys and Humans

被引:25
|
作者
Iwasaki, Kazuhide [2 ]
Murayama, Norie [1 ]
Koizumi, Ryo [1 ]
Uno, Yasuhiro [3 ]
Yamazaki, Hiroshi [1 ]
机构
[1] Showa Pharmaceut Univ, Tokyo 1948543, Japan
[2] Shin Nippon Biomed Labs, Osaka, Japan
[3] Shin Nippon Biomed Labs, Wakayama, Japan
关键词
CYP3A4; CYP3A5; cynomolgus monkey; human; HUMAN LIVER-MICROSOMES; CATALYTIC ROLES; OXIDATION; VARIANTS; HYDROXYLATION; METABOLISM; INDUCTION; JAPANESE; CYP3A4; P450S;
D O I
10.2133/dmpk.DMPK-10-NT-022
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug metabolizing activities of cytochromes P450 (P450s, or CYPs) 3A4 and 3A5 in liver microsomes from the cynomolgus monkey [Macaca fascicularis (mf)] were investigated and compared with those of human P450 3A enzymes. Low activities for dealkylation of ethoxyresorufin and pentoxyresorufin were seen in recombinant monkey mfCYP3A4 and mfCYP3A5 and in recombinant human CYP3A4 and CYP3A5 expressed in bacterial membranes. Hydroxylation activities of mfCYP3A4 and mfCYP3A5 toward coumarin, paclitaxel, diclofenac, flurbiprofen, and S-mephenytoin were below detectable levels, as was also true for CYP3A4 and CYP3A5. Monkey mfCYP3A5 and mfCYP3A4 were highly active in bufuralol 1'-hydroxylation. mfCYP3A5 was efficient at dextromethorphan O-demethylation, although human CYP3A5 was unable to catalyze this reaction. Apparent bufuralol 1'-hydroxylation and dextromethorphan O-demethylation activities of monkey liver microsomes were higher than those of human liver microsomes, possibly because of contributions of mfCYP3A5 to these P450 2D-dependent drug oxidations. mfCYP3A5 and CYP3A5 catalyzed midazolam 1'-hydroxylation at a low substrate concentration more efficiently than the corresponding CYP3A4. mfCYP3A5 had higher testosterone 6 beta-hydroxylase activity than mfCYP3A4, but the reverse relationship was observed in oxidation of nifedipine and hydroxylation of dexamethasone. These results demonstrate that monkey P450 3A enzymes have similar substrate selectivity to that of human P450 3A enzymes, but exhibit wider substrate selectivity toward P450 2D substrates.
引用
收藏
页码:388 / 391
页数:4
相关论文
共 50 条
  • [41] Thermophilic cytochrome P450 enzymes
    Nishida, CR
    de Montellano, PRO
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 338 (01) : 437 - 445
  • [42] Cytochrome P450 enzymes in the heart
    Park, BK
    LANCET, 2000, 355 (9208): : 945 - 946
  • [43] Cloning, expression, and characterization of cytochrome P450 3A in minipig
    Soucek, P
    Anzenbacher, P
    Zuber, R
    Anzenbacherová, E
    Guengerich, FP
    TOXICOLOGY, 2001, 164 (1-3) : 146 - 146
  • [44] Cytochrome P450 3A polymorphisms and immunosuppressive drugs:: an update
    Anglicheau, Dany
    Legendre, Christophe
    Beaune, Philippe
    Thervet, Eric
    PHARMACOGENOMICS, 2007, 8 (07) : 835 - 849
  • [45] Cytochrome P450 3A pharmacogenetics: the road that needs traveled
    Flockhart, DA
    Rae, JM
    PHARMACOGENOMICS JOURNAL, 2003, 3 (01): : 3 - 5
  • [46] EFFECT OF CANNABIDIOL (CBD) ON CYTOCHROME P450 3A IN THE MOUSE
    BORNHEIM, LM
    EVERHART, ET
    LI, J
    FASEB JOURNAL, 1993, 7 (03): : A265 - A265
  • [47] EXPRESSION AND CHARACTERIZATION OF CYNOMOLGUS CYTOCHROME P450 3A4
    Subramanian, Murali
    Bhutani, Priyadeep
    Selvakumar, Sindhuja
    Ghosh, Kaushik
    Krishnamurthy, Prasad
    Rami, Bhadresh
    Kallipatti, Sanjith
    Sukrutharaj, Sunil
    Selvam, Sabariya
    Halan, Vivek
    Ramarao, Manjunath
    Mandlekar, Sandhya
    DRUG METABOLISM REVIEWS, 2014, 45 : 89 - 89
  • [48] Cytochrome P450 3A pharmacogenetics: the road that needs traveled
    D A Flockhart
    J M Rae
    The Pharmacogenomics Journal, 2003, 3 : 3 - 5
  • [49] How important is intestinal cytochrome P450 3A metabolism?
    van Herwaarden, Antonius E.
    van Waterschoot, Robert A. B.
    Schinkel, Alfred H.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2009, 30 (05) : 223 - 227
  • [50] Cytochrome P450 3A: Genetic polymorphisms and interethnic differences
    Krishna, DR
    Shekar, MS
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2005, 27 (08): : 559 - 567